AnaptysBio's Ulcerative Colitis Drug Trial Fails

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded10 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198545

Show notes

AnaptysBios ulcerative colitis drug trial, rosnilimab, failed to meet main goals, leading to a twenty percent stock drop. Despite safety and patient tolerance, the drug showed no significant improvement for moderate to severe ulcerative colitis patients after twelve weeks. The company decided to discontinue the trial, saving at least ten million dollars. AnaptysBio plans to separate drug development from royalty assets by 2026, expecting around three hundred million dollars by the end of 2025, including a seventy-five million dollar payment from GSK.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.